Preclinical studies in melanoma have also revealed that combined BRAF and MEK inhibition induces cancer cell death via pyroptosis – a highly inflammatory form of programed cell death (66), which triggers an anti-tumor immune response that persists even after drug treatment is completed. The gene discussed is MAP2K7; the disease is melanoma.